Viewing Study NCT07214532

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:42 PM
Ignite Modification Date: 2026-06-17 @ 7:33 PM
Study NCT ID: NCT07214532
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-12-23
First Post: 2025-09-24
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Sponsor: Natera, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Neoplasms View
None Carcinoma, Ductal, Breast View
None Receptors, Estrogen (for ER-positive Requirement) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None ctDNA View
None Circulating tumor DNA View
None Signatera View
None CDK4/6 inhibitor View
None Ribociclib View
None Abemaciclib View
None Molecular residual disease View
None MRD View
None Biomarker-guided therapy View
None Adjuvant therapy View
None Hormone receptor positive View
None HER2 negative View
None Early breast cancer View
None Intermediate risk breast cancer View
None breast cancer View
None Endocrine therapy View
None Tumor-informed assay View